Multiple Sclerosis Update: Biogen, Sanofi, Active, Adamas and Novartis

Biogen successfully fended off a patent challenge from generic company Mylan over its multiple sclerosis (MS) drug Tecfidera. Mylan had filed an inter partes review hoping to overturn the last of Biogen’s Tecfidera patent, but the U.S. Patent Trial and Appeal Board ruled in Biogen’s favor. The patent won’t expire until 2028. The drug brought in $4.43 billion in 2019.